Author

Kelly Bumgarner

Observed name: Kelly Feist Bumgarner

Observed institutions: University of Nevada, Las Vegas, Levine Cancer Institute

OpenAlex ID: A5041996642

The Impact of Pedestrian Crossing Flags on Driver Yielding Behavior in Las Vegas, NV

2019 · Sheila Clark, Courtney Coughenour, et al. · Sustainability · 18

Interventions that increase the intention to seek voluntary HIV testing in young people: a review

2016 · Kelly Feist Bumgarner, Jennifer Pharr, et al. · AIDS Care · 11

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma

2026 · Shebli Atrash, James Symanowski, et al. · Blood Advances · 2

Final Results of Phase 1 Clinical Trial of Belantamab Mafodotin Combined with Carfilzomib, Lenalidomide, and Dexamethasone for Multiple Myeloma after One to Three Prior Lines of Therapy

2024 · Shebli Atrash, James Symanowski, et al. · Blood · 1

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

2019 · Shebli Atrash, Myra Robinson, et al. · Blood · 1

OA-57 Results of a Phase 1 Clinical Trial of Belantamab Mafadotin (BelMaf) Combined With Carfilzomib, Lenalidomide, and Dexamethasone (KRd) for Multiple Myeloma (MM) After One Prior Line of Therapy (LOT)

2024 · Shebli Atrash, James Symanowski, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 6

Citation count: 33

H-index: 2

I10-index: 2